Literature DB >> 3135313

Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus.

Y P Huang1, L H Perrin, P A Miescher, R H Zubler.   

Abstract

There have been only a few studies indicating that B cell hyperactivity in SLE could depend on Th cell activation. In particular, circulating CD4+ cells were found to express Ia. Our own previous investigations have shown that the decreased IL-2 secretion capacity in vitro of CD4+ cells in SLE is restored to normal when the cells are rested for a few days in culture. This suggested the presence of activated, exhausted T cells in the circulation. In this study, we report several observations concerning T cell function in SLE. 1) Decreased IL-2 secretion in vitro of PBL was found to correlate significantly with increased spontaneous IgG secretion of such cells; immunosuppressive treatment of 22 patients with steroids plus cyclosporin A led, to a large extent, to a correction of both abnormalities. 2) 9 of 18 patients with active disease (and low IL-2 secretion in vitro) had increased IL-2 levels in serum by ELISA; two sera contained IL-2 biologic activity, and chromatography of one serum showed IL-2 in a high molecular size complex (Mr approximately 50,000) dissociable with 6 M urea. The serum levels of IL-2R were also frequently increased, even in less active SLE. 3) In cell culture experiments, the IgG secretion by purified B cells from 6 of 9 patients with active SLE was increased by autologous T cells acting either alone (3 patients) or synergistically with rIL-2 (3 patients); the B cells from all 9 patients showed increased IL-2 responsiveness compared with blood donor B cells. Taken together, these results provide new evidence that increased T cell activation occurs and plays a role in SLE.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3135313

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

Review 1.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

2.  Increased concentrations of soluble interleukin-2 receptor in the serum of patients with systemic sclerosis.

Authors:  P Airò; M Bettinzioli; R Gorla; R Cattaneo
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

3.  IL-10 production in multiple sclerosis patients, SLE patients and healthy controls: preliminary findings.

Authors:  M Gelati; E Lamperti; A Dufour; E Corsini; E Venegoni; C Milanese; A Nespolo; A Salmaggi
Journal:  Ital J Neurol Sci       Date:  1997-08

4.  Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus.

Authors:  Y Tokano; A Murashima; Y Takasaki; H Hashimoto; K Okumura; S Hirose
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

5.  Evaluation of serum levels of soluble interleukin-2 receptor as an indicator of disease activity in systemic lupus erythematosus.

Authors:  P Airŏ; S Braga; E Prati; D Brugnoni; M Bettinzioli; R Gorla; R Cattaneo
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

Review 6.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

7.  Drug-combination therapy of rheumatoid arthritis.

Authors:  P A Miescher; H Favre; R Lemoine; P Tamagnini
Journal:  Springer Semin Immunopathol       Date:  1998

8.  A long-term immunological study of childhood onset systemic lupus erythematosus.

Authors:  C K Ting; K H Hsieh
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

Review 9.  Refractory idiopathic immune thrombocytopenic purpura in children: current and future treatment options.

Authors:  Paul Imbach
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.

Authors:  K L Lim; A C Jones; N S Brown; R J Powell
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.